# US 2026/0117196 A1 · Compositions and methods for obtaining human intestinal tissue and related uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0117196 A1
- Document ID: US20260117196A1
- Status: Published application
- Kind: A1
- Application number: 19/374,947
- Filed: 2025-10-30
- Published: 2026-04-30
- Earliest claimed: 2024-10-30
- Assignees: The Regents of the University of Michigan
- Applicants: The Regents of the University of Michigan
- Inventors: Madeline Eiken; Charlie Childs; Jason Spence
- Web page: https://patentgrep.com/patent/US20260117196A1

## CPC

- C12N 5/0697: {Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels C12N5/0691)}
- C12N 5/0018: {Culture media for cell or tissue culture (media for specific animal cell type C12N5/06)}
- C12N 5/0679: {Cells of the gastro-intestinal tract}
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/16: Activin; Inhibin; Mullerian inhibiting substance
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2502/081: neurons
- C12N 2502/1347: Smooth muscle cells
- C12N 2502/23: Gastro-intestinal tract cells
- C12N 2506/02: from embryonic cells
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2510/00: Genetically modified cells
- C12N 2513/00: 3D culture
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention disclosed herein generally relates to methods and systems for converting stem cells into specific tissue(s) or organ(s) through directed differentiation. In particular, the invention disclosed herein relates to methods and systems for promoting human intestinal tissue (e.g., human intestinal organoid tissue) comprising epithelium, stroma, neurons, endothelial cells, and organized smooth muscle, and interstitial cells of Cajal (ICCs).

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A method for producing human intestinal organoid tissue derived from human pluripotent stem cells, comprising:
(i) culturing hindgut spheroid tissue in a first medium comprising added epiregulin (EREG) to differentiate the hindgut spheroid tissue; and
(ii) maintaining or expanding the hindgut spheroid tissue in a second medium comprising added EREG to obtain human intestinal organoid tissue comprising epithelial cells, stromal cells, neural cells, endothelial cells, smooth muscle cells, and interstitial cells of Cajal (ICCs).

### Claim 21 (depends on 20)

The method of claim 20, wherein the added EREG concentration in the first medium and/or second medium is at least 1 ng/ml.

### Claim 22 (depends on 20)

The method of claim 20, wherein the first medium further comprises a BMP signaling pathway inhibitor and/or a Wnt signaling pathway inhibitor.

### Claim 23 (depends on 22)

The method of claim 22, wherein the BMP signaling pathway inhibitor is Noggin and the Wnt signaling pathway inhibitor is R-Spondin 1.

### Claim 24 (depends on 20)

The method of claim 20, wherein the first medium and/or the second medium does not contain epidermal growth factor (EGF).

### Claim 25 (depends on 20)

The method of claim 20, wherein the first medium and/or the second medium does not contain neuregulin 1 (NRGT).

### Claim 26 (depends on 20)

The method of claim 20, wherein the duration of hindgut spheroid tissue differentiation into human intestinal organoid tissue is at least 10 hours.

### Claim 27 (depends on 20)

The method of claim 20, wherein the epithelial cells express CDX2, the neural cells express TUBB3 and/or MAP2, the endothelial cells express PECAM and/or CDH5, and/or the smooth muscle cells express SM22 and/or TAGLN at the protein and/or RNA level.

### Claim 28 (depends on 20)

The method of claim 20, wherein the human intestinal organoid tissue spontaneously and/or rhythmically contracts.

### Claim 29

A composition comprising human intestinal organoid tissue derived from human pluripotent stem cells, wherein the human intestinal organoid tissue comprises epithelial cells, stromal cells, neural cells, endothelial cells, smooth muscle cells, and interstitial cells of Cajal (ICCs).

### Claim 30 (depends on 29)

The composition of claim 29, wherein the human intestinal organoid tissue culture medium comprises added epiregulin (EREG).

### Claim 31 (depends on 30)

The composition of claim 30, wherein the added EREG concentration in the medium is at least 1 ng/ml.

### Claim 32 (depends on 29)

The composition of claim 29, wherein the neural cells comprise neuronal and glial cells.

### Claim 33 (depends on 29)

The composition of claim 29, wherein the epithelial cells express CDX2, the neural cells express TUBB3 and/or MAP2, the endothelial cells express PECAM and/or CDH5, and the smooth muscle cells express SM22 and/or TAGLN at the protein and/or RNA level.

### Claim 34 (depends on 29)

The composition of claim 29, wherein the human intestinal organoid tissue has been maintained and/or expanded for at least 10 hours.

### Claim 35 (depends on 29)

The composition of claim 29, wherein the human pluripotent stem cells are human induced pluripotent stem cells or human embryonic stem cells.

### Claim 36 (depends on 29)

The composition of claim 29, wherein the human intestinal organoid tissue is genetically engineered.
